RC220 is ready right now so there is no waiting, but the answer your question about why not pursue AML it is purely a matter of money.
To pursue AML commercially the next step is to run a Phase 2/3 pivotal trial (we would be able to get away with only one Phase 3 trial as AML is an orphan indication). The cost of running such a trial is on the order of US$100 - $150m (A$160 - $240m). In the current biotech funding environment raising such a level of capital without diluting every existing shareholder to oblivion is impossible. Even if we were willing to do this to our shareholders, at our current MC it would likely still be impossible.
Find me someone willing to invest $500m in RAC at a $20 a share valuation and we can talk about AML. In the meantime we will continue to work within the constraints of commercial reality and focus on creating the maximum return for our shareholders. The good news is with the resources we have we can still pursue an amazing opportunity in CPACS.
RAC Price at posting:
$1.14 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)